



ORIGINAL ARTICLE

Evaluation of a neonatal screening program for sickle-cell disease^{☆,☆☆}



Rodrigo Eller^{a,*}, Denise Bousfield da Silva^b

^a Medical School, Universidade Federal de Santa Catarina (UFSC), Florianópolis, SC, Brazil

^b Department of Pediatrics, Universidade Federal de Santa Catarina (UFSC), Florianópolis, SC, Brazil

Received 14 June 2015; accepted 21 October 2015

Available online 15 February 2016

KEYWORDS

Sickle cell disease;
Neonatal screening;
Santa Catarina State

Abstract

Objective: Evaluate the Neonatal Screening Program of the Health Secretariat of the State of Santa Catarina for sickle-cell disease, from January 2003 to December 2012, regarding program coverage and disease frequency.

Methods: Descriptive, observational, cross-sectional study with retrospective data collection. The variables analyzed were: number of live births in the State of Santa Catarina; number of screened children; number of children diagnosed with sickle-cell trait and sickle-cell disease; type of sickle-cell disease diagnosed; age at the time of sample collection, ethnicity/skin color, gender, and origin of children with sickle-cell disease. Descriptive measures and frequency tables were used for data analysis.

Results: During the study period, there were 848,833 live births and 730,412 samples were screened by the program, resulting in a coverage of 86.0%. There were 6173 samples positive for sickle-cell trait and 39 for sickle-cell disease. Among children with sickle-cell disease, the median age at the time of sample collection was 6 days. Regarding the ethnicity/skin color, 25 (64.1%) children were white, seven were black, and seven others were not specified. The Midwest and the Highland (Planalto Serrano) of Santa Catarina were the regions with the highest incidence of sickle-cell disease.

Conclusion: Coverage by the Neonatal Screening Program of Santa Catarina is good, but did not demonstrate an improvement trend over the years. The frequency of sickle-cell disease is low and lower than in the North, Northeast, and Midwest regions. The median age in days at the time of collection is older than the age recommended by the Ministry of Health.

© 2016 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

[☆] Please cite this article as: Eller R, Silva DB. Evaluation of a neonatal screening program for sickle-cell disease. J Pediatr (Rio J). 2016;92:409–13.

^{☆☆} Article associated to Hospital Infantil Joana de Gusmão, Florianópolis, SC, Brazil.

* Corresponding author.

E-mail: rodrigoellersrl@gmail.com (R. Eller).

PALAVRAS-CHAVE

Doença falciforme;
Triagem neonatal;
Estado de Santa
Catarina

Avaliação de um programa de triagem neonatal para doença falciforme**Resumo**

Objetivo: avaliar o Programa de Triagem Neonatal da Secretaria de Saúde do Estado de Santa Catarina (PTN-SES/SC) para doença falciforme no período de janeiro de 2003 a dezembro de 2012, em relação à sua cobertura e à frequência da doença.

Métodos: estudo descritivo, observacional e transversal com coleta retrospectiva dos dados. As variáveis analisadas foram: número de nascidos-vivos no Estado de Santa Catarina; número de crianças triadas; número de crianças diagnosticadas com traço e doença falciforme (DF); tipo de DF diagnosticada; idade da coleta, cor/raça, sexo e procedência das crianças com DF. Foram utilizadas as medidas descritivas e as tabelas de frequência para análise dos dados.

Resultados: no período estudado, houve 848.833 nascidos-vivos e 730.412 amostras triadas pelo programa, gerando cobertura de 86,0%. Das amostras triadas, foram encontradas 6.173 crianças com traço falciforme e 39 com DF. Entre as crianças com DF, a mediana da idade em dias na data da coleta foi de 6. Das 39 crianças doentes, 25 (64,1%) eram da cor/raça branca, 7 da negra e 7 de outra cor/raça. As regiões do planalto serrano e do meio-oeste de Santa Catarina foram as regiões com maior incidência de DF.

Conclusões: a cobertura do PTN-SES/SC é boa, contudo não apresentou tendência de melhora ao longo dos anos. A frequência da DF é baixa e menor que nas regiões Norte, Nordeste e Centro-oeste. A mediana da idade em dias no momento da coleta está acima do preconizado pelo Ministério da Saúde.

© 2016 Sociedade Brasileira de Pediatria. Publicado por Elsevier Editora Ltda. Este é um artigo Open Access sob uma licença CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Sickle-cell disease (SCD) represents a group of autosomal-recessive inherited hematological diseases, which includes several genotypes, with a prevalence of hemoglobin S (HbS).¹⁻³ The presence of this abnormal hemoglobin is responsible for the main clinical manifestations of the disease, which originate from vaso-occlusive phenomena and chronic ischemic disorders.⁴

The distribution of SCD is a heterogeneous one and is more common among those of African ascendancy. According to 2009 data from the Brazilian Institute of Geography and Statistics (Instituto Brasileiro de Geografia e Estatística – IBGE), in Brazil, black and brown individuals represented 6.9% and 44.2% of the population, respectively, reflecting the heterogeneity of SCD in the country.⁵

In June 2001, through Ministry of Health Decree No. 822, several diseases were added to the list of those screened through the existing National Neonatal Screening Program (NSP) (phenylketonuria and congenital hypothyroidism), to include the detection of SCD and other hemoglobinopathies, as well as cystic fibrosis.⁶ The diagnosis of SCD is performed by a laboratory through the detection of HbS and its association with quantitative fractions of other hemoglobins.

The NSP, together with multidisciplinary care, has allowed a significant reduction in morbidity and mortality from the disease, as shown by studies in other countries.⁶

The aim of this study was to evaluate the NSP of the Health Secretariat of the State of Santa Catarina (Programa de Triagem Neonatal da Secretaria da Saúde do Estado de Santa Catarina [NSP-SES/SC]) for SCD and other hemoglobinopathies in relation to their coverage and the

incidence of SCD and sickle-cell trait from January 2003 to December 2012.

Methods

This was a descriptive, observational, cross-sectional study approved by the Ethics Committee of Hospital Infantil Joana de Gusmão under opinion No. 029/2013.

The assessed variables were obtained retrospectively from a database at the Central Laboratory (Laboratório Central [LACEN]) of the Health Secretariat of the State of Santa Catarina (Secretaria da Saúde do Estado de Santa Catarina [SES/SC]) and the Live Birth Information System (Sistema de Informações sobre Nascidos Vivos [SINASC]). The collected data comprise the period from January 2003 to December 2012.

The variables included: number of live births in the State of Santa Catarina; number of children screened by the NSP-SES/SC for SCD and other hemoglobinopathies; number of children diagnosed with SCD and sickle-cell trait by the NSP-SES/SC; type of SCD diagnosed by the aforementioned program; final diagnosis of children whose first samples were inconclusive; age at collection, ethnicity/skin color, gender, and origin of children with SCD according to the macro-regions of Santa Catarina.⁷

Regarding the variable ethnicity/skin color, it used the criterion established by the Brazilian Institute of Geography and Statistics (Instituto Brasileiro de Geografia e Estatística [IBGE]).⁵ The information on this variable was obtained from the file completed by the nursing staff at the time of blood sample collection.

Blood sample collection was carried out by the nursing staff in hospitals, maternity hospitals, or basic health units

in the municipalities of Santa Catarina. The sample, taken from the child's heel and deposited on filter paper discs, was later sent to LACEN for analysis.

The method used to test blood samples was high-performance liquid chromatography associated with the cation-exchange chromatography, using the Variant II device (Bio-Rad®, CA, USA).

Samples with results different from the Hb FA pattern were submitted to another distinct chromatography test. The isoelectric focusing test was usually used for this assessment. When the results of both tests were distinct, constituting an inconclusive result, the child was called for a new sample collection.

Children whose samples had an indeterminate result, i.e., a hemoglobin type different from the hemoglobin that can be identified by standard screening tests, were referred for diagnostic clarification at Hospital Infantil Joana de Gusmão (HIJG), a referral center in the State of Santa Catarina for neonatal screening tests.

Descriptive measures and frequency tables were used for analysis of the results.

Results

From January 2003 to December 2012, 730,412 samples were submitted to screening test of the NSP-SES/SC. During this period, 848,833 children were born in the state, according to SINASC, which indicates a program coverage of 86.0% (Table 1).

SCD was identified in 39 children of the screened samples. Of these, 26 cases showed the FS pattern (in order of decreasing quantity, presence of hemoglobins F and S, in the absence of hemoglobin A); 12 FSC (presence of hemoglobins F, S and C, in the absence of hemoglobin A); and one FSA (presence of hemoglobins F, S and A; Table 2). Each of these samples was submitted to two tests – high-performance liquid chromatography and isoelectric focusing – with

Table 1 Number of live births, screened children, and percentage of coverage of the Neonatal Screening Program of the Health Secretariat of the State of Santa Catarina, from January 2003 to December 2012.

Year	Live births ^a	Screened children ^b	Coverage
2003	83,177	67,993	81.7%
2004	85,475	80,243	93.9%
2005	84,584	80,333	95.8%
2006	84,133	68,063	80.9%
2007	81,903	69,925	85.4%
2008	85,262	80,172	94.0%
2009	83,489	73,437	88.0%
2010	84,611	61,997	73.3%
2011	87,481	78,127	89.3%
2012	88,772	70,122	78.0%
Total	848,833	730,412	86.0%

No justifications were found for the low coverage in 2010.

^a Live Birth Information System (Sistema de Informações sobre Nascidos Vivos [SINASC]).⁷

^b Central Laboratory (Laboratório Central [LACEN]) of the Health Secretariat of the State of Santa Catarina.

Table 2 Number of children with sickle-cell trait and disease diagnosed by the Neonatal Screening Program of the Health Secretariat of the State of Santa Catarina, from January 2003 to December 2012.

Year	FAS pattern	FS pattern	FSC pattern	FSA pattern
2003	491	3	2	0
2004	666	5	1	0
2005	655	3	2	1
2006	550	3	2	0
2007	607	0	0	0
2008	692	2	3	0
2009	659	6	1	0
2010	509	1	0	0
2011	683	1	0	0
2012	661	2	1	0
Total	6173	26	12	1

Source: Central Laboratory (Laboratório Central [LACEN]) of the Health Secretariat of the State of Santa Catarina.

equivalent results. Whether there was further confirmation of the results with other diagnostic tests was not assessed.

The result was indeterminate in 302 samples, i.e., the hemoglobin was different from hemoglobins that can be diagnosed by neonatal screening methods. These children were referred to the HIJG for diagnostic clarification.

Of the samples analyzed by the NSP-SES/SC, 41 showed inconclusive results and 25 children with these results did not undergo a second test, despite the program's recommendation. Of the remaining 16 children that had a new sample collected, six once again showed an inconclusive pattern, seven showed a normal pattern, and three had sickle-cell trait pattern. Thus, 31 children with an inconclusive pattern did not have a definite diagnosis (Fig. 1).

Regarding the origin, the Midwest and Highland macro-regions had the highest percentages of SCD cases (Table 3).

Regarding the skin color/ethnicity of children with SCD (patterns FS, FSC, and FSA), 25 (64.1%) were white; seven were black, and seven were of ethnicity/skin color not specified in the sample collection form. As for gender, 24 were males and 15 were females. The mean age on the sample collection day was 9.08 days and the median was 6 days.

Discussion

The main result of this study was to confirm the frequency of SCD (1:18,728) and sickle-cell trait (1:118) in the State of Santa Catarina, as well as the coverage of the neonatal screening program in the state (86.0%).

The incidence of SCD was low, possibly due to the small proportion of African descendants in the State of Santa Catarina. Blacks, according to IBGE, accounted for only 2.2%, and mixed-race, 11.7% of the state population in the year 2009.⁵ The highest SCD incidence occurred in the Midwest and Highland macro-regions of Santa Catarina.

In Brazil, in 2003, the incidence of SCD was 1:650 in Bahia, the state with the highest proportion of blacks in the population,⁸ while in Rio de Janeiro it was 1:1288 in 2007.⁹ However, a study carried in 2004 in Rio Grande do Sul showed an incidence of SCD of 1:39,100,¹⁰ and another performed




Figure 1 Number of live births, screened samples, and respective diagnoses at the NSP-SES/SC, from January 2003 to December 2012.

in Paraná between 2002 and 2004 showed an incidence of 1:20,320.¹¹

The observed coverage may not reflect the actual screening coverage of all live births. Even though all the municipalities in the state have joined this program, some children may have been screened in the private health care network, which does not generate record for the NSP-SES/SC and reflects a failure of the state's monitoring program.

In studies conducted in Brazil, it was observed that the program coverage in the Federal District was 83.4% in 2006¹²; in Bahia, 88.9% between the years 2007 and 2009¹³; and in Mato Grosso do Sul, 91.8% between 2006 and 2010.¹⁴ The goal of 100% coverage of the neonatal screening programs is still a challenge, even in more developed countries.⁹ Canada and Belgium, in 2006, achieved coverage of 76%¹⁵ and 87%,¹⁶ respectively.

Among the children with SCD in the period analyzed in this study, the mean age on sample collection day was 8.58 days and the median was 6 days, showing the need to improve these variables, as the Ministry of Health recommends that the collection be performed between 3 and 5 days of life. Although the test can be performed later, it is

of utmost importance to collect the sample within the ideal period for some of the screened diseases, in order to provide early diagnosis and treatment, as well as to benefit from the prevention of sequelae.

A higher number of white patients was observed (64.1%) among the 39 SCD cases. The higher incidence of the disease in whites can be explained by the higher number of these individuals among the State of Santa Catarina's population, which, according to 2009 IBGE data, accounted for 85.7% of the total population,⁵ in addition to the white ethnicity being misattributed to the mixed-race population. The data limitation regarding skin color/ethnicity originates from the fact that this information is filled out by the person who completed the blood sample form and not based on a detailed family background questionnaire, considering the interpretative disagreement between skin color and ethnicity of a particular individual. It is essential, however, to be aware that none of these limitations affect the major aspects assessed in this study.

Regarding children with inconclusive and indeterminate results, it is important to create mechanisms to intensify the search for these individuals, aiming to expand the program's

Table 3 Distribution of sickle-cell disease per health macro-region of the State of Santa Catarina, from January 2003 to December 2012.

Health macro-region	Number of cases of sickle cell disease ^a	Number of live births per region	Incidence per region
Great-West	0	97,705	0
Midwest	8	86,921	1:10,865
North highlands	1	56,624	1:56,624
Northeast	8	122,663	1:15,333
Itajaí Valley	1	120,420	1:120,420
Itajaí river estuary	5	76,502	1:15,300
Highland	4	42,259	1:10,565
Greater Florianópolis	10	129,362	1:12,932
South	2	116,427	1:58,213
Total	39	848,883	1:18,728

Source: Live Birth Information System (Sistema de Informações sobre Nascidos Vivos [SINASC])⁷ and Central Laboratory (Laboratório Central [LACEN]) of the Health Secretariat of the State of Santa Catarina.

^a Sickle-cell disease (FS, FSC, and FSA).

scope and to identify and provide early treatment to any SCD carriers – which in this study was of a low frequency, considering the number of screened samples.

One limitation of this study is due to lack of patient monitoring after diagnosis through the neonatal screening, in order to assess patient adherence to the interdisciplinary outpatient follow-up and health measures proposed by the program. Recently, a study performed in Minas Gerais found that neonatal screening in that state, even if carried out in a comprehensive and effective manner, was not enough to reduce SCD mortality, which was 7.4% in the first 14 years, with slightly more than half of the deaths occurring before 2 years of age.¹⁷

The drastic reduction in mortality related to SCD in the early years of life, from 26% to 1–2%, occurred due to comprehensive care provided to this population at pediatric referral centers. Therefore, early diagnosis and treatment of SCD helps to increase survival and significantly improves the quality of life of these individuals.^{6,18}

Thus, it can be concluded that the NSP has good coverage in Santa Catarina and that the incidence of SCD in the state is quite low. Nevertheless, it is essential to assess patients' adherence to health measures recommended by the NSP, as without this follow-up, the diagnosis alone becomes pointless. With the information provided by this study, the authors intend to seek the affected children and assess adherence to outpatient medical follow-up, as well as the health support offered to patients, in order to actually evaluate the program's efficacy.

Conflicts of interest

The authors declare no conflicts of interest.

References

1. Lobo CL, Ballas SK, Domingos AC, Moura PG, do Nascimento EM, Cardoso GP, et al. Newborn screening program for hemoglobinopathies in Rio de Janeiro, Brazil. *Pediatr Blood Cancer*. 2014;61:34–9.
2. Campos Júnior D, Burns DA, Lopez FA. *Tratado de pediatria: Sociedade Brasileira de Pediatria*. 3rd ed. Rio de Janeiro: Manole; 2014.
3. Kliegman RM. *Nelson tratado de pediatria*. 14th ed. Rio de Janeiro: Elsevier; 2014.
4. Goldman L, Ausiello D. *Cecil medicina*. 23rd ed. Rio de Janeiro: Elsevier; 2009.
5. Instituto Brasileiro de Geografia e Estatística. *Síntese de indicadores sociais: uma análise das condições de vida da população brasileira 2010*. Available from: <http://biblioteca.ibge.gov.br/visualizacao/livros/liv45700.pdf> [cited 01.09.14].
6. Hassel KL. Population estimates of sickle cell disease in the U.S. *Am J Prev Med*. 2010;38:S512–21.
7. Tabnet. Departamento de Informática do Sistema Único de Saúde (DATASUS). Available from: <http://tabnet.datasus.gov.br/cgi/deftohtm.exe?sinasc/cnv/nvsc.def> [cited 01.09.14].
8. Almeida A, Godinho TM, Teles MS, Rehem APP, Jalil HM, Fukuda TG, et al. Avaliação do programa de triagem neonatal na Bahia no ano de 2003. *Rev Bras Saúde Matern Infant*. 2006;6:85–91.
9. Botler J, Camacho LA, Cruz MM. Phenylketonuria, congenital hypothyroidism and haemoglobinopathies: public health issues for a Brazilian newborn screening program. *Cad Saude Publica*. 2012;28:1623–31.
10. Sommer CK, Goldbeck AS, Wagner SC, Castro SM. Triagem neonatal para hemoglobinopatias: experiência de um ano na rede pública do Rio Grande do Sul, Brasil. *Cad Saude Publica*. 2006;22:1709–14.
11. Watanabe AM, Pianovski MA, Zanis Neto J, Lichtvan LC, Chautard-Freire-Maia EA, Domingos MT, et al. Prevalência da hemoglobina S no estado do Paraná, Brasil, obtida pela triagem neonatal. *Cad Saude Publica*. 2008;24:993–1000.
12. Diniz D, Guedes C, Barbosa L, Tauil PL, Magalhães I. Prevalência do traço falciforme e da anemia falciforme em recém-nascidos do Distrito Federal, Brasil, 2004 a 2006. *Cad Saude Publica*. 2009;25:188–94.
13. Amorim T, Pimentel H, Fontes MIMM, Purificação A, Lessa P. Avaliação do Programa de Triagem Neonatal na Bahia entre 2007 e 2009 – As lições da doença falciforme. *Gaz Med Bahia*. 2010;80:10–3.
14. Ivo ML, Araujo OM, Barbieri AR, Corrêa Filho RA, Pontes ER, de Oliveira Botelho CA. Scope and efficiency of the newborn screening program in identifying hemoglobina S. *Rev Bras Hematol Hemoter*. 2014;36:14–8.
15. Therrell BL, Adams J. Newborn screening in North America. *J Inherit Metab Dis*. 2007;30:447–65.
16. Loeber G. Neonatal screening in Europe: the situation in 2004. *J Inherit Metab Dis*. 2007;30:430–8.
17. Sabarense AP, Lima GO, Silva LM, Viana MB. Characterization of mortality in children with sickle cell disease diagnosed through the Newborn Screening Program. *J Pediatr (Rio J)*. 2015;91:242–7.
18. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. *Blood*. 2010;115:3447–52.